♟️ Tuesday 9 June 2026 Tue, 9 June 2026

Zenith Minerals urges shareholders to accept Forrestania Resources’ takeover offer valuing Zenith at a 78.6% premium to its 30-day VWAP, promising access to near-term production and a stronger combined gold portfolio.

Saferoads Holdings (ASX: SRH) has acquired Chameleon AMLS, adding a new modular trailer product line and appointing its founder Andrew Kaye to the board.

Imugene’s off-the-shelf CAR T therapy azer-cel has won FDA Fast Track Designation for relapsed or refractory CLL/SLL and MZL, backed by compelling Phase 1b response rates.

Spenda Limited (ASX:SPX) has kicked off an $8.545 million accelerated entitlement offer at a steep discount, aiming to strengthen its balance sheet, reduce debt, and support its strategic reset towards profitability.

OncoSil Medical has cleared a major regulatory hurdle as its Humanitarian Device Exemption application nears FDA approval, while its TRIPP-FFX trial shows promising results combining OncoSil with standard chemotherapy for pancreatic cancer.

Elanor Investors Group has finalised a $125 million recapitalisation that slashes its cost of capital and reduces debt, setting the stage for a leaner, capital-light funds management model and imminent ASX reinstatement.

Heavy Rare Earths Limited has appointed Jason Barnett as Managing Director and CEO, aiming to leverage his extensive mining experience as the company advances its critical minerals projects and prepares for a maiden drilling campaign.

Astron Limited’s updated economic study for Phase 2 of its Donald Rare Earth and Mineral Sands Project reveals a $1.5 billion incremental pre-tax NPV8 and a mine life extended to 52 years, doubling ore throughput and reinforcing the project’s long-term strategic value.

American West Metals has struck a significant continuous 108.4m interval of high-grade indium mineralisation at its West Desert Project, expanding the known resource and confirming a large-scale skarn system with zinc, gold, silver, and copper by-products.

Alterity Therapeutics has clinched FDA agreement on the pivotal Phase 3 trial design for ATH434, targeting Multiple System Atrophy, with the trial set to begin by the end of 2026.

Forrestania Resources has launched a recommended off-market takeover bid for Zenith Minerals, valuing Zenith at about A$93.5 million with a 46.7% premium. The deal aims to create a larger, diversified Western Australian gold explorer and developer.

Lindian Resources has cancelled 13 million performance rights held by a former executive chairman, sparking uncertainty as a potential $10 million claim looms.

Ovanti Limited has inked a four-year exclusive partnership with Yuno.trade, positioning itself as the payment processor and technology backbone for a new licensed prediction market platform targeting Southeast and Central Asia.

Mont Royal Resources has unveiled an updated Preliminary Economic Assessment for its Ashram Rare Earths Project, confirming robust economics and a long mine life with strategic importance for Western critical minerals supply chains.

Yari Minerals has rebranded as Yari Resources and appointed Courtney Taylor as Managing Director to sharpen its focus on Queensland’s Bowen Basin coal assets. The company is advancing its Rolleston South project with a technical review and performance incentives for directors.

Maritana Minerals has increased the processing capacity of its Black Swan Processing Hub to 2.5 million tonnes per annum, with construction set to begin mid-2026 and first production expected in the second half of 2027.

Synlait Milk is progressing a key refinancing of its senior bank facilities due June 2026 and plans to replace a $130 million shareholder loan with a two-year term facility. The company reports a preliminary $12 million net loss for the first four months of 2026 amid operational headwinds and asset sales.